Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro

J Drug Target. 2008 Aug;16(7):601-4. doi: 10.1080/10611860802228954.

Abstract

Long-circulating liposomes loaded with doxorubicin (Dox) were additionally modified with the prostate cell-specific monoclonal antibody 5D4 (mAb 5D4). The resultant Dox-loaded 5D4-immunoliposomes specifically recognized prostate cancer cell lines of several different types expressing the mAb 5D4 antigen, PSMA, and significantly enhanced cytotoxicity toward these cells compared with the non-targeted Dox-liposomes in vitro while no increased toxicity was observed toward non-prostate (lung) cancer cell line.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / therapeutic use
  • Cell Line, Tumor
  • Doxorubicin / administration & dosage*
  • Doxorubicin / therapeutic use
  • Drug Carriers*
  • Drug Delivery Systems*
  • Humans
  • Liposomes*
  • Male
  • Particle Size
  • Prostatic Neoplasms / immunology*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Drug Carriers
  • Liposomes
  • Doxorubicin